In conclusion, in this large, unselected and single institution series of patients with CLL autoimmune cytopenias correlated with well-known poor prognostic variables but not with treatment modality (i.e. purine analogs vs. alkylating agents). From the prognostic point of view, autoimmune cytopenias did not significantly influenced prognosis in the whole group of patients. Moreover, patients presenting with advanced disease related to an immune mechanism had better prognosis than those in whom advanced stage reflected a high tumor burden only. These results emphasize the importance of determining the origin of cytopenias in patients with CLL for both treatment and prognostic purposes.
No relevant conflicts of interest to declare.
This icon denotes an abstract that is clinically relevant.
Asterisk with author names denotes non-ASH members.